Early decrements in bone density after completion of neoadjuvant chemotherapy in pediatric bone sarcoma patients by Müller, Carsten et al.
RESEARCH ARTICLE Open Access
Early decrements in bone density after
completion of neoadjuvant chemotherapy
in pediatric bone sarcoma patients
Carsten Müller
1*, Corinna C Winter
1,D i e t e rR o s e n b a u m
1, Joachim Boos
2, Georg Gosheger
3, Jendrik Hardes
3,V o l k e rV i e t h
4
Abstract
Background: Bone mineral density (BMD) accrual during childhood and adolescence is important for attaining
peak bone mass. BMD decrements have been reported in survivors of childhood bone sarcomas. However, little is
known about the onset and development of bone loss during cancer treatment. The objective of this cross-
sectional study was to evaluate BMD in newly diagnosed Ewing’s and osteosarcoma patients by means of dual-
energy x-ray absorptiometry (DXA) after completion of neoadjuvant chemotherapy.
Methods: DXA measurements of the lumbar spine (L2-4), both femora and calcanei were performed
perioperatively in 46 children and adolescents (mean age: 14.3 years, range: 8.6-21.5 years). Mean Z-scores, areal
BMD (g/cm
2), calculated volumetric BMD (g/cm
3) and bone mineral content (BMC, g) were determined.
Results: Lumbar spine mean Z-score was -0.14 (95% CI: -0.46 to 0.18), areal BMD was 1.016 g/cm
2 (95% CI: 0.950 to
1.082) and volumetric BMD was 0.330 g/cm
3 (95% CI: 0.314 to 0.347) which is comparable to healthy peers. For
patients with a lower extremity tumor (n = 36), the difference between the affected and non-affected femoral neck
was 12.1% (95% CI: -16.3 to -7.9) in areal BMD. The reduction of BMD was more pronounced in the calcaneus with
a difference between the affected and contralateral side of 21.7% (95% CI: -29.3 to -14.0) for areal BMD.
Furthermore, significant correlations for femoral and calcaneal DXA measurements were found with Spearman-rho
coefficients ranging from r = 0.55 to r = 0.80.
Conclusions: The tumor disease located in the lower extremity in combination with offloading recommendations
induced diminished BMD values, indicating local osteopenia conditions. However, the results revealed no
significant decrements of lumbar spine BMD in pediatric sarcoma patients after completion of neoadjuvant
chemotherapy. Nevertheless, it has to be taken into account that bone tumor patients may experience BMD
decrements or secondary osteoporosis in later life. Furthermore, the peripheral assessment of BMD in the calcaneus
via DXA is a feasible approach to quantify bone loss in the lower extremity in bone sarcoma patients and may
serve as an alternative procedure, when the established assessment of femoral BMD is not practicable due to
endoprosthetic replacements.
Background
Survival rates in pediatric sarcoma patients have con-
tinuously improved within the last decades due to mod-
ern multi-agent chemotherapeutic protocols and
improvements in diagnostic methods [1,2]. Therefore,
the sequelae attributed to the disease or its treatment
like a diminished bone mineral density (BMD) are gain-
ing more interest [3] and have been reported previously
in pediatric sarcoma patients [4-7]. In this age group a
development towards peak bone mass should be
observed [8]. Factors negatively influencing BMD in sar-
coma patients are polychemotherapy [9], a deficient
nutritional status [10], reduced physical activity levels
[11,12], and a delayed onset of puberty [13,14] and may
correspond with an increased risk of pathologic frac-
tures [15,16]. However, there is still little evidence from
current research on the onset and development of bone
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high risk for diminished BMD during treatment and
thus pathologic fractures due to the location of bone
sarcomas.
Therefore, the first hypothesis is that children and
adolescents undergoing treatment for bone sarcomas
reveal BMD decrements already after completion of
neoadjuvant chemotherapy. This effect may be ascribed
to the disease process and polychemotherapeutic
medications.
Secondly, limited mobility for patients with a tumor
located in the vicinity of weight-bearing joints in the
lower extremity, e.g. pelvis or knee region, may induce
more pronounced BMD deficits compared with patients
affected in the upper extremity. While neoadjuvant che-
motherapy is supposed to have a systemic impact on
BMD status, the disease process as well as immobiliza-
tion in patients with a primary tumor disease in the
lower extremity may result in rarefaction and local
pathologic bone loss.
Furthermore, patients with a tumor located in the
femur or tibia are strongly advised to offload the
affected extremity after biopsy due to an increased frac-
ture risk. This is not the case in patients with sarcomas
located in the pelvis or the fibula. Hence, we expected
significant differences in BMD between the affected and
non-affected, contralateral femoral neck and calcaneus
with pronounced bone loss in patients with femoral or
tibial sarcomas, although the extent of BMD loss in the
affected extremity is unknown.
Lastly, the feasibility of peripheral calcaneal BMD
assessment via DXA will be evaluated, since the assess-
ment of femoral BMD is often impossible due to endo-
prosthetic replacements of the proximal femur.
Therefore, the objectives of the present study are to
evaluate the BMD status in pediatric bone sarcoma
patients on completion of neoadjuvant chemotherapy to
extract patients being at high risk for low bone density
at this early stage of treatment and to evaluate the feasi-
bility of calcaneal DXA measurements.
Methods
Patients
Pediatric Ewing’s and osteosarcoma patients who met
the following criteria were eligible for this cross-
sectional study (Table 1): 8-21 years of age, Caucasian
origin, and completion of neoadjuvant chemotherapy.
Exclusion criteria were: start of adjuvant chemothera-
peutic treatment, previous irradiation, and chronic dis-
eases. The study protocol was approved by the local
Ethics Committee (2006-216-f-s) and the Federal Office
for Radiation Protection (Z5-22462/2-2006-081). All
parents and patients, if they attained full age, gave writ-
ten informed consent.
A reference database [17] was used for the determina-
tion of Z-scores for height and weight in patients below
the age of 18 years. Z-scores for patients above 18 years
of age were calculated by means of an internet database,
published by the German Federal Statistical Office [18].
Patients’ anthropometrics were comparable to healthy
c o n t r o l sw i t hr e s p e c tt ob o d yh e i g h tt h a td i dn o td i f f e r
significantly. The weight of the patient group was
slightly lower (not significant), and the body mass index
(BMI) was significantly decreased (p = 0.001, Table 1).
Assessment of Bone Mineral Density (BMD)
Dual-energy X-ray absorptiometry (DXA) scans were
performed with a Lunar Prodigy system (enCORE 2006,
Software Version 10.51.006, GE Healthcare, UK). Data
were automatically compared with the integrated
NHANES III Reference Database for the lumbar spine
to obtain Z-scores, used in the pediatric population.
Z-scores below -2 SD indicate low BMD for a compar-
able chronologic age [19]. DXA derived BMD values are
expressed as areal density (areal BMD in g/cm
2). These
values are dependent on bone size thus introducing
potential errors when determining the BMD status of
Table 1 Anthropometric and demographic data of the
patient group
Participants Mean (95% CI)
Female/Male 19 (41.3%)/27 (58.7%)
Age (years) at diagnosis 13.9 (13.0 to 14.9)
Age (years) at measurement 14.3 (13.3 to 15.2)
Caucasian 46 (100%)
Height (m)/Z-score 1.64 (1.59 to 1.69)/0.07 (-0.04 to 0.19)
Weight (kg)/Z-score 52.2 (47.5 to 56.9)/-0.31 (-0.51 to -0.10)
BMI (kg/m
2)/Z-score 18.9 (17.9 to 20.0)/-1.03 (-1.55 to -0.51) *
Low BMD (Z-score ≤ -1SD) (2 females, 11 males)
Age (years) at measurement 14.8 (13.1 to 16.4)
BMI (kg/m
2)/Z-score 18.7 (16.5 to 20.9)/-1.67 (-3.04 to -0.30)†
Weight (kg)/Z-score 52.2 (43.7 to 60.7)/-0.68 (-1.24 to -0.12)†
Normal BMD (Z-score >
-1SD)
(17 females, 16 males)
Age (years) at measurement 14.1 (12.9 to 15.3)
BMI (kg/m
2)/Z-score 19.0 (17.7 to 20.4)/-0.44 (-0.89 to 0.0)†
Weight (kg)/Z-score 52.2 (46.2 to 58.1)/-0.20 (-0.43 to 0.02)†
Localisation (Female/Male)
Upper extremity 4 (8.7%)/6 (13.0%) ∑ 10 (21.7%)
Lower extremity 15 (32.6%)/21 (45.7%) ∑ 36 (78.3%)
Femur/Tibia 12 (26.1%)/17 (37.0) ∑ 29 (63.0%)
Pelvis/Fibula 3 (6.5%)/4 (8.7%) ∑ 7 (15.2%)
Total 46 (100%)
CI = confidence interval, BMI = body mass index, ∑ = sum, * significant
difference between patient group and healthy control group, † significant
difference between patients with low BMD (Z-score lumbar spine ≤ -1) and
patients with normal BMD status (Z-score lumbar spine > -1)
Müller et al. BMC Musculoskeletal Disorders 2010, 11:287
http://www.biomedcentral.com/1471-2474/11/287
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Kroger et al. [20] was used to calculate volumetric den-
sity (volumetric BMD in g/cm
3). In this model, the ver-
tebral body is considered as a cylindrical shape so that
the volume of the cylinder can be calculated using the
following formula:
Volumetric BMD Areal BMD  4  x width =× () [/ ] 
The same applies to the volumetric BMD of the
femoral neck by means of the calculation:
Volumetric BMD Areal BMD 4 height width =× () ( ) /* / 
S i n c eZ - s c o r e sw e r eo n l ya v a i l a b l ef o rt h el u m b a r
spine in pediatric patients, reference data published by
van der Sluis et al. [21], including areal and volumetric
BMD values, were additionally used to evaluate possible
decrements in bone density in the patient group.
Calcaneal DXA measurements were facilitated by a
modification of the distal radius analysis with reposition-
ing the range of interest (ROI) within the medial calca-
neus (Figure 1).
BMD measurements were performed perioperatively
on completion of neoadjuvant chemotherapy and before
continuing adjuvant chemotherapy in the lumbar spine
(L2-4), both femoral necks and both calcanei if feasible.
Quality assurance was performed by calibrating the
DXA system with a spine phantom supplied by the
manufacturer. Coefficients of variation (CV) for repeated
measurements were between 0.6% and 0.25%.
Statistical Analyses
The Mann-Whitney U-test was used for the comparison of
BMD of the patient group and reference data from a
healthy control group [21]. Mann-Whitney U-test was
applied for the comparison of BMD in Ewing’s and osteo-
sarcoma patients as well as in male and female patients.
Furthermore, the Kruskal-Wallis H-test was applied for the
comparison of different primary tumor locations (upper
extremity, femur/tibia, pelvis/fibula) and the Mann-
Whitney U-Test and Bonferroni correction for pairwise
comparisons of the three locations (p value = 0.0167).
Wilcoxon signed rank tests were used for the comparison
of areal BMD, volumetric BMD and BMC of the affected
and non-affected femoral neck and areal BMD and BMC of
the affected and contralateral calcaneus for those patients
undergoing treatment for a lower extremity sarcoma. Only
complete data sets (available for left and right sides) were
used for statistical analyses. Furthermore, Spearman corre-
lation coefficients were calculated for the relationship
between calcaneal and femoral neck BMD and BMC.
Results
DXA measurements of the lumbar spine revealed
slightly diminished BMD values for the patient group
after completion of neoadjuvant chemotherapy with a
mean Z-Score of -0.14 (95% CI: -0.46 to 0.18). Z-scores
ranged from -2.1 to 2.2. Thirteen patients (28.3%) pre-
sented lumbar spine Z-scores below -1 and one patient
(2.2%) had low BMD for a comparable chronologic age
with a Z-score below -2 (Table 1). Patients with lumbar
spine Z-scores below -1 had equal BMI values compared
to patients with BMD values greater than -1, but
Z-scores for weight and BMI were significantly lower.
Mean values for areal BMD were 1.016 g/cm
2 (95%
CI: 0.950 to 1.082) and 1.013 g/cm
2 (95% CI: 0.960 to
1.066) for the patient group and the reference data
group [21], respectively. Differences between both
groups were not statistically significant. Calculated volu-
metric BMD values again revealed no significant differ-
ences in the lumbar spine BMD for the comparison of
the patient group (vBMD = 0.330 g/cm
3, 95% CI: 0.314
to 0.347) with reference data (vBMD = 0.328 g/cm
3,
95% CI: 0.318 to 0.339) [21].
The comparison of lumbar spine BMD in upper extre-
mity (mean Z-score -0.44, 95% CI: -0.94 to 0.06) and
lower extremity sarcoma patients (mean Z-score -0.06,
95% CI: -0.45 to 0.34) revealed no significant difference.
However, Ewing’s sarcoma patients, whose neoadjuvant
treatment lasts 18 weeks and includes six cycles of
chemotherapy, revealed a significant lower lumbar spine
Z-score (-0.61, 95% CI: -1.15 to -0.07) compared with
osteosarcoma patients (0.14, 95% CI: -0.25 to 0.52, p =
0.016), whose neoadjuvant treatment lasts ten weeks
with two cycles of chemotherapy.
Figure 1 Implementation of peripheral calcaneal BMD
assessment via DXA.
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-0.37 (95% CI: -0.78 to 0.03) than in female patients with
0.19 (95% CI: -0.34 to 0.72) but did not differ signifi-
cantly. Only one female patient, undergoing treatment
for a Ewing’s sarcoma located in the acetabulum, had a
Z-score lower than -2 and hence low bone density
already after completion of neoadjuvant chemotherapy.
In addition, we found the lowest lumbar spine BMD
values in patients undergoing treatment for pelvic
(Z-score -1.08, 95% CI: -1.98 to -0.17) or upper extremity
sarcomas (Z-score -0.44, 95% CI: -0.94 to 0.06, Table 2).
The third hypothesis was that BMD decrements may
occur locally as a consequence of offloading recommen-
dations in patients with primary tumor locations in the
lower extremity. Theref o r e ,t h eB M Ds t a t u si n
the affected and non-affected, contralateral sides of the
femoral neck and calcaneus were evaluated. Wilcoxon
signed-rank tests revealed significant decrements (p <
0.001) in the affected compared with the non-affected,
contralateral side of the femoral neck and the calcaneus
(Table 3). Decreased BMD values were more pro-
nounced in the calcaneus (p = 0.014) with -21.7% (95%
CI: -29.3 to -14.0) for areal BMD and -21.7% (95%
CI: -29.4 to -14.1) for BMC than in the femoral neck with
-12.1 (95% CI: -16.3 to -7.9) for areal BMD and -11.1
(95% CI: -16.9 to -5.3) for volumetric BMD (Figure 2).
Furthermore, mean percent changes in BMD between
affected and contralateral femoral neck and calcaneus
were greatest for patients with sarcomas located in the
weight-bearing bones, i.e. femur and tibia (Table 4). They
accounted for 13% between both femoral necks and 23%
between both calcanei. Femoral and calcaneal BMD in the
affected extremity declined to a lesser extent in patients
with primary tumor locations in the pelvis or the fibula
(not significant).
Post-surgery tumor-endoprosthetic replacements or
difficulties in patient positioning for bone density analy-
sis via DXA may complicate the assessment of femoral
BMD or even prevent DXA application. Therefore, the
feasibility of peripheral BMD assessment of the calca-
neus was assessed. Data obtained from femoral and cal-
caneal sites were correlated to evaluate whether this
approach may serve as an alternative BMD assessment
with peripheral DXA in a population of pediatric sar-
coma patients. Both, the affected and contralateral sides
of the femoral neck and calcaneus were significantly
correlated with Spearman-rho correlation coefficients
ranging from r = 0.55 and r = 0.80 (Table 5).
Discussion
To our knowledge this is the first study determining the
BMD status of children and adolescents undergoing
Table 2 Effect of tumor location on BMD expressed as Z-
scores and percent compared to healthy age and gender
matched controls
Mean (95% CI) Mean (95% CI) p-value
Lumbar spine
Z-score
Age comparison
[%]
Upper Extremity
(n = 10)
-0.44 (-0.94 to 0.06) 94.5 (88.4 to
100.6)
0.393*
Lower Extremity
(n = 36)
-0.06 (-0.45 to 0.34) 99.2 (94.4 to
103.9)
Upper Extremity
(n = 10)
-0.44 (-0.94 to 0.06) 94.5 (88.4 to
100.6)
0.284†
Femur/Tibia
(n = 29)
0.03 (-0.39 to 0.45) 100.2 (95.3 to
105.2)
Pelvis/Fibula
(n = 7)
-0.40 (-1.72 to 0.92) 94.7 (78.2 to
111.2)
CI = confidence interval
* Mann-Whitney U-test, † Kruskal Wallis H-test
Table 3 Mean BMD and BMC values of the affected and
contralateral femoral neck and calcaneus for lower
extremity sarcoma patients
Scan region Affected
Mean (95% CI)
Contralateral
Mean (95% CI)
p-value*
FN (n = 29)
aBMD (g/cm
2) 0.877 (0.794 to 0.959) 0.993 (0.922 to 1.064) p < 0.001
vBMD (g/cm
3) 0.358 (0.328 to 0.388) 0.402 (0.384 to 0.420) p < 0.001
BMC (g) 4.18 (3.66 to 4.69) 4.75 (4.22 to 5.28) p < 0.001
Calc (n = 25)
aBMD (g/cm
2) 0.457 (0.391 to 0.523) 0.583 (0.524 to 0.641) p < 0.001
BMC (g) 1.47 (1.26 to 1.68) 1.87 (1.69 to 2.06) p < 0.001
BMD = bone mineral density, aBMD = areal bone mineral density (g/cm
2),
vBMD = volumetric bone mineral density (g/cm
3), BMC = bone mineral content,
CI = confidence interval,F N= femoral neck, Calc = calcaneus
* Mann-Whitney U-test
Figure 2 aBMD differences between affected and contralateral
sides of the femoral neck and calcaneus. Boxplots represent
median, 25
th and 75
th percentile, 1.5 interquartile range (IQR) and
outliers.
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Page 4 of 8treatment for bone sarcomas with respect to local osteo-
penia conditions. All enrolled patients received neoadju-
vant chemotherapy according to the protocols of
Euramos-1 (osteosarcoma) and Euro-E.W.I.N.G.99
(Ewing’s sarcoma) thus representing a comparatively
homogenous patient group within each protocol. After
completion of neoadjuvant chemotherapy no significant
decrease in lumbar spine BMD was observed. Obtained
data rather indicate that bone loss occurs primarily in
terms of focal osteopenia within the affected extremity.
This is confirmed by the significantly decreased BMD of
-12.1% of the femoral neck when comparing the affected
and contralateral side. On the other hand, differences in
BMD of the calcaneus between affected and contralateral
sides were significantly higher and accounted for -21.7%.
Unexpected, only one female patient with a low lumbar
spine BMD status after completion of neoadjuvant che-
motherapy for a bone sarcoma located in the acetabulum
was found. However, patients with a tumor located in the
pelvis revealed the lowest lumbar spine BMD with an aver-
age Z-score of -1.08. Z-scores for the whole patient group
indicate that there is only a slight, but non-significant
reduction in lumbar spine BMD in this early stage of treat-
ment. Most probable, bone formation is already decreased
after completion of neoadjuvant chemotherapy, but BMD
decrements using DXA may not yet be detectable.
Patients with primary tumor locations in the lower
extremity were expected to present lower lumbar spine
Z-scores due to adhering to offloading recommenda-
tions or impaired gait as a consequence to tumor related
pain and subsequently reduced physical activity levels. In
fact, patients with upper extremity tumors revealed
lower lumbar spine Z-scores of -0.44 compared to Z-
scores of patients treated for lower extremity sarcomas
with -0.06, even though the difference between both
groups was not significant.
Previous studies on BMD in sarcoma patients focused
on survivors and found reduced BMD values [4,5,7,22].
Kaste et al. [7] examined 99 survivors of rhabdomyosar-
coma, osteosarcoma and Ewing’s sarcoma at least one
year after completion of polychemotherapy and found a
decreased BMD status with a median Z-score of -0.75.
Low BMD was correlated with younger age at diagnosis
and treatment with cyclophosphamide in rhabdomyosar-
coma patients. Neither medications with methotrexate
(MTX), ifosfamide nor endocrinopathies were correlated
with diminished BMD values. Findings of a higher risk
for low bone density in patients with primary upper
extremity sarcomas compared with lower extremity
tumor patients were confirmed in the present study.
Holzer et al. [4] found reduced BMD values in two
thirds of 48 adult survivors of osteosarcoma: 44%
revealed osteopenic and 21% osteoporotic values. Ruza
et al. [5] reported an even higher incidence of osteope-
nia in 60% and osteoporosis in 27% of 63 osteosarcoma
and Ewing’s sarcoma patients six years after diagnosis.
This indicates that BMD loss is likely to occur in pedia-
tric bone sarcoma survivors; it may develop in the long
run and persist for several years. Longitudinal studies
are necessary to define the occurrence of diminishing
bone density. Therefore, the assessment of BMD should
already be incorporated during the acute treatment
phase and should be repeated every six months, since
sarcoma patients are at increased risk for developing
low BMD during and after treatment. The reasons are
likely to be multifactorial and include extensive adjuvant
chemotherapy, radiation, premature gonadal hormone
failure, and reduced physical activity levels. However,
serial densitometry screens by means of DXA in
Table 4 Mean percent difference in BMD between affected and contralateral side in sarcoma patients
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Location n= aBMD (g/cm
2) vBMD (g/cm
3) BMC (g)
FN UpEx 10 -1.3 (-5.8 to 3.3) -3.2 (-10.2 to 3.9) 3.3 (-5.6 to 12.1)
Femur/Tibia 22 -13.7 (-18.8 to -8.5) -12.7 (-20.1 to -5.3) -13.6 (-18.1 to -9.1)
Pelvis/Fibula 7 -7.1 (-14.6 to 0.4) -6.2 (-13.8 to 1.5) -7.8 (-15.5 to 0.0)
Calc UpEx 8 -4.4 (-9.3 to 0.4) -4.3 (-9.0 to 0.5)
Femur/Tibia 19 -22.5 (-30.1 to -15.0) -22.6 (-30.1 to -15.1)
Pelvis/Fibula 6 -18.8 (-47.9 to 10.3) -18.9 (-47.8 to 10.0)
* Lower extremity sarcoma patients subgrouped into sarcomas within the vicinity of primary weight-bearing joints (femur/tibia) and pelvis/fibula.
CI = confidence interval, aBMD = areal bone mineral density (g/cm
2), vBMD = volumetric bone mineral density (g/cm
3), BMC = bone mineral content (g),U p E x=
Upper Extremity,F N= femoral neck, Calc = calcaneus
Table 5 Spearman correlation coefficients for BMD of the
femoral neck and calcaneus in patients with a primary
tumor located in the lower extremity (n = 24)
Bone Density r = p-value
aBMD affected 0.654 0.001
aBMD contralateral 0.798 <0.001
BMC affected 0.549 0.005
BMC contralateral 0.741 <0.001
vBMDfemur - aBMDcalcaneus affected 0.649 0.001
vBMDfemur - aBMDcalcaneus contralateral 0.694 <0.001
BMC = bone mineral content, aBMD = areal bone mineral density, vBMD =
volumetric bone mineral density
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to interpret, since they depend on gender, body size,
and pubertal stage [13,23,24].
High doses of methotrexate are part of neoadju-
vant chemotherapy in osteosarcomas. This agent is
known to negatively affect bone metabolism by
means of increasing bone resorption and to inhibit
bone formation by affecting the differentiation of
early osteoblastic cells [25]. Therefore, osteosarcoma
patients were assumed to reveal lower BMD values than
patients undergoing treatment for Ewing’s sarcoma. This
c o u l dn o tb ec o n f i r m e di nt h ep r e s e n tc r o s s - s e c t i o n a l
study. Ewing’s sarcoma patients had significantly lower
lumbar spine Z-scores. Most likely the difference between
both diagnosis groups is due to a significantly shorter
duration of neoadjuvant treatment in osteosarcoma
patients with two cycles of chemotherapeutic agents
(methotrexate, adriamycin and cisplatin) in ten weeks in
comparison to 18 weeks of neoadjuvant treatment and six
cycles VIDE (vincristine, ifosfamide, doxorubicin and eto-
posid/cisplatin) in Ewing’s sarcoma patients. While ten
weeks of treatment do not seem to be linked with a signifi-
cant loss of lumbar spine BMD in osteosarcoma patients,
neoadjuvant treatment with nearly twice the time and
more than twice the dose intensity in Ewing’ss a r c o m a
patients induced significant lumbar spine BMD. Longitu-
dinal studies with particular focus on osteosarcoma
patients would help to clarify this hypothesis. However,
our findings are in accordance with previous studies by
Arikoski et al. [26,27] who demonstrated normal BMD
values for the lumbar spine and femoral neck at diagnosis
in a heterogeneous group of pediatric patients with differ-
ent cancer entities, even though bone formation was
already decreased. The diminishing effect on BMD due to
impaired bone turnover was not shown until six months
of polychemotherapy [28].
The results of the present study demonstrate that
bone loss exists in pediatric sarcoma patients after
neoadjuvant chemotherapy in terms of focal osteopenia.
Regional low BMD status can be explained as an effect
of offloading recommendations for patients with a lower
extremity sarcoma. Since the calcaneus is mainly com-
posed of trabecular bone that is known to react faster to
metabolic changes than cortical bone, the reduced load
on the affected leg and in particular on the calcaneus is
supposed to result in a rapid reduction of BMD [29].
Thus, the present results confirm a recent study quanti-
fying postoperative bone loss in children [30]. Regional
lower BMD is attributable to prolonged immobilization
and limited weight-bearing. The awareness of a tumor
in the lower extremity leads to a cautious movement
behaviour with a further load reduction. This finding of
local BMD loss in pediatric patients with solid cancer is
in accordance with previous findings [6].
This study extends available information on BMD
decrements in pediatric sarcoma patients by determining
the differences between affected and non-affected lower
extremity bone density. Sarcoma patients experience a
mean regional bone loss of up to 13% in the femoral
neck and 23% in the calcaneus already after preoperative
chemotherapy. The highest difference for femoral areal
BMD of 45% was found in a male patient treated for
Ewing’s sarcoma located in the distal femur. After local
therapy, usually consisting of tumor surgery, lower
extremity sarcoma patients have to continue offloading
the affected extremity. Patients undergoing tumor sur-
gery for a pelvic sarcoma are confined to bed for at
least six weeks. Cementless reconstructions of the femur
afford offloading of the affected leg with a subsequent
gradually increase of the load of ten kg per week. After
recovery from surgery, sarcoma patients show reduced
activity levels due to restrictions to the ward and gait
impairments [31]. This implies that bone strength is lost
as a consequence of immobilization [32]. Therefore, the
extent of BMD loss in the affected leg has to be deter-
mined in future longitudinal studies. New strategies like
promotion of physical activity while undergoing cancer
treatment as well as an immediate reintegration after
cessation of tumor therapy will have to be established to
prevent significant bone loss due to cancer treatment. It
should be evaluated whether exercise interventions are
feasible in sarcoma patients and which loads are essen-
tial for the affected extremity.
Furthermore, the present results reveal that peripheral
DXA measurements performed at the calcaneus can
serve as an alternative for the generally established
assessment of BMD in the femoral neck region, espe-
cially in cases where femoral DXA measurements are
not feasible due to common problems in pediatric bone
sarcoma patients like positioning difficulties or endo-
prosthetic replacements.
Finally, several limitations of this study have to be
acknowledged. The first refers primarily to the patient
group. Although only bone sarcoma patients were enrolled
in this study, they represent a fairly heterogeneous sample
due to different age groups (8-21 years) and treatment
protocols (Euramos-1 and Euro-E.W.I.N.G.99). While the
Euramos-1 protocol for osteosarcoma patients consists of
ten weeks of neoadjuvant treatment in which methotrex-
ate, adriamycin and cisplatin are administered, patients
within the Euro-E.W.I.N.G. 99 protocol receive six cycles
VIDE (vincristine, ifosfamide, doxorubicin and etoposid/
cisplatin) of neoadjuvant chemotherapy prior to local ther-
apy within 18 weeks on average.
Furthermore, treatment-related delay of pubertal
maturation may have a substantial impact on BMD in
bone sarcoma patients [14]. Therefore, the lack of a
Tanner stage assessment allows no unequivocal
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BMD decrements in bone sarcoma patients.
The implementation of peripheral DXA assessment of
calcaneal BMD was not performed with a pDXA instru-
ment as described in literature [33], but a whole body
axial scanner. Since our intention was not the develop-
ment of reference values but the determination of
changes in BMD between the affected and contralateral
extremity, using an axial DXA scanner was appropriate.
Finally, due to a lack of pediatric anthropometric data
from the German Federal Statistical Office we had to
refer to a second database for patients below the age of
18 years [17].
Conclusions
In summary, childhood and adolescence represent a cri-
tical time with respect to attaining peak bone mass.
Treatment for bone sarcomas may interfere with the
accumulation of an appropriate peak bone mass and
hence may lead to an increased fracture risk in adult-
hood, constituting a significant reduction in quality of
life. Exercise intervention programs are essential and
should begin immediately after diagnosis. Screening
patients at risk for low BMD should already start at the
beginning of cancer treatment and be repeated in regu-
lar intervals of six to twelve months. Peripheral BMD
evaluation of the calcaneus is a relevant and appropriate
procedure, in particular when established femoral neck
DXA measurements are not feasible due to common
endoprosthetic replacements in sarcoma patients.
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